Small intestine neuroendocrine tumour – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:17:43 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Small intestine neuroendocrine tumour – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Efficacy of 177Lu-DOTATATE as Adjuvant Therapy After Surgery for Stage III Small Intestinal Neuroendocrine Tumors https://clinicaltrials.eu/trial/efficacy-of-177lu-dotatate-as-adjuvant-therapy-after-surgery-for-stage-iii-small-intestinal-neuroendocrine-tumors/ Wed, 29 Apr 2026 15:06:11 +0000 https://clinicaltrials.eu/trial/efficacy-of-177lu-dotatate-as-adjuvant-therapy-after-surgery-for-stage-iii-small-intestinal-neuroendocrine-tumors/ Small intestinal neuroendocrine neoplasms (SI-NEN) are tumors that develop in the small intestine from cells that release hormones. This study examines whether adding a treatment called peptide receptor radionuclide therapy (PRRT) after surgery can help prevent cancer from returning. PRRT is a type of radioligand therapy that delivers radiation directly to tumor cells by attaching to specific receptors on these cells.

The purpose of this study is to determine if patients who receive PRRT after complete surgical removal of their tumor have a longer time without cancer recurrence compared to patients who only receive standard monitoring. Participants in this study will be randomly assigned to either receive PRRT (experimental group) or undergo regular surveillance with no additional treatment (control group). Both groups will be monitored for at least 60 months (5 years) to track if and when the cancer might return.

Throughout the study, participants will undergo imaging tests called PET-CT scans that use special tracers to detect if there are any new tumors. They will also complete questionnaires about their quality of life. The study will track side effects of the treatment and measure how long participants remain free of disease and their overall survival rates.

]]> Study on Reducing Side Effects of Lutetium (177Lu) Oxodotreotide in Patients with Advanced Midgut Neuroendocrine Tumors https://clinicaltrials.eu/trial/study-on-reducing-side-effects-of-lutetium-177lu-oxodotreotide-in-patients-with-advanced-midgut-neuroendocrine-tumors/ Wed, 29 Apr 2026 15:04:05 +0000 https://clinicaltrials.eu/trial/study-on-reducing-side-effects-of-lutetium-177lu-oxodotreotide-in-patients-with-advanced-midgut-neuroendocrine-tumors/ This clinical trial is focused on studying a type of cancer known as neuroendocrine tumors that originate in the midgut, which includes parts of the small intestine and the right side of the colon. These tumors are often slow-growing and can be difficult to treat when they become advanced or spread to other parts of the body. The treatment being tested in this study is called Lu177-Dotatate, a form of targeted therapy that uses a radioactive substance to deliver treatment directly to the cancer cells. This therapy is given as a solution through an infusion into the veins.

The purpose of the study is to see if giving Lu177-Dotatate every 16 weeks, instead of every 8 weeks, can reduce the side effects related to blood health, such as low blood cell counts, in patients with these tumors. Participants in the study will receive the treatment at different intervals, and their health will be monitored over time to assess the impact on their condition and any side effects they experience. The study aims to find a balance between effective treatment and minimizing adverse effects.

Throughout the study, participants will undergo regular health check-ups and assessments to monitor their response to the treatment and any changes in their condition. The study is designed to last for several years, allowing researchers to gather comprehensive data on the long-term effects and benefits of the treatment schedule. The ultimate goal is to improve the quality of life for patients with advanced neuroendocrine tumors by finding a treatment regimen that is both effective and less taxing on the body.

]]> Study of 64Cu-DOTATATE and 18F-FDG PET/CT imaging to predict disease progression in patients with neuroendocrine neoplasms https://clinicaltrials.eu/trial/study-on-pet-ct-imaging-with-64cu-dotatate-and-18f-fdg-for-patients-with-neuroendocrine-tumors/ Wed, 29 Apr 2026 15:00:27 +0000 https://clinicaltrials.eu/trial/study-on-pet-ct-imaging-with-64cu-dotatate-and-18f-fdg-for-patients-with-neuroendocrine-tumors/ This study focuses on patients with Neuroendocrine Neoplasms (tumors that develop from cells of the hormone system). The research uses two different imaging substances: 64Cu-DOTATATE and 18F-FDG, which are special solutions given through an injection into a vein. These substances help create detailed images of tumors using a special type of scanning called PET/CT (a combination of two imaging techniques that produces detailed pictures of the body’s internal structures).

The purpose of this study is to develop new ways to predict how long patients with neuroendocrine neoplasms might remain stable without their disease getting worse. This will be done by analyzing measurements from combined scans using both imaging substances. During the study, participants will receive both types of imaging solutions and undergo PET/CT scanning.

Both imaging substances are given as single injections into a vein. 64Cu-DOTATATE attaches to specific receptors found on neuroendocrine tumors, while 18F-FDG helps show how active the tumor cells are. The combination of these two different types of scans provides doctors with more complete information about the tumor’s characteristics and behavior.

]]>